Li C, Vides A, Kim D, Xue J, Zhao Y and Lito P. The G-protein signaling regulator RGS3 enhances the GTPase activity of KRAS. Science. 2021 Oct 8;374(6564):197-201. PMID: 34618566 

Zhao Y, Murciano-Goroff Y, Xue Y, Ang A, Lucas J, Da Cruz Paula A, Mai T, Sisk A, Arora K, Roy R, Kim D, Li C, Lim L, Li M, Bahr A, Loomis B, de Stanchina E, Reis-Filho J, Weigelt B, Berger M, Riely G, Arbour K, Lipford R, Li B and Lito P. Diverse genetic alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021 Nov 10; 599(7886):679-683. doi: 10.1038/s41586-021-04065-2. PMID: 34759319

Kim D, Xue J and Lito P. Targeting KRAS G12C: from inhibitory mechanism to modulation of antitumor effect in patients. Cell, 2020. Oct 14:S0092-8674(20)31241-1. PMID: 33065029

Hong DS*, Fakih MG, Strickler JH, Desai J, Durm JA,Shapiro GI, Falchook GS, Price TJ, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Lito P*, Govindan R*, Li BT*. KRAS G12C inhibition in advanced solid tumors. New England Journal of Medicine, 2020. Sep 24;383(13):1207-1217. PMID: 32955176 * Equal contribution/co-senior authors

Xue J and Lito, P. Quest for clinically effective RAF dimer inhibitors. Journal of Clinical Oncology. 2020 May 20:JCO2000401. PMID: 32432945

Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, Kim D, Li C, de Stanchina E, Mazutis L, Risso D, Lito P. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577(7790):421-5. doi: 10.1038/s41586-019-1884-x. PMID: 31915379

Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF, 3rd, Cassidy DP, Marx MA, Rybkin, II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Janne PA, Olson P, Christensen JG. The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discovery. 2020;10(1):54-71. doi: 10.1158/2159-8290.CD-19-1167.  PMID: 31658955

Wang VE, Xue JY, Frederick DT, Cao Y, Lin E, Wilson C, Urisman A, Carbone DP, Flaherty KT, Bernards R, Lito P, Settleman J, McCormick F. Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. Clinical Cancer Research. 2019;25(23):7202-17. doi: 10.1158/1078-0432.CCR-18-2779. PMID: 31515463

Mai TT, Lito P. A treatment strategy for KRAS-driven tumors. Nature Medicine. 2018;24(7):902-4. doi: 10.1038/s41591-018-0111-x. PMID: 29988139

Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, Lito P, Berger M, Solit DB, Hellmann M, Kris MG, Rudin CM, Ni A, Arcila M, Ladanyi M, Riely GJ. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clinical Cancer Research. 2018;24(2):334-40. doi: 10.1158/1078-0432.CCR-17-1841. PMID: 29089357

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P. An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer. Nature Medicine. 2017;23(8):929-37. doi: 10.1038/nm.4369. PMID: 28714990

Xue Y, Lito P. Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required. Clinical Cancer Research. 2017;23(6):1365-7. doi: 10.1158/1078-0432.CCR-16-2576. PMID: 27923842

Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, Kris MG, Riely GJ, Lito P, Iqbal A, Veach S, Smith-Marrone S, Sarkaria IS, Krug LM, Rudin CM, Travis WD, Rekhtman N, Pietanza MC. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer. 2016. doi: 10.1016/j.cllc.2016.01.003. PMID: 26898325

Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351(6273):604-8. doi: 10.1126/science.aad6204. PMID: 26841430

Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014;25(5):697-710. doi: 10.1016/j.ccr.2014.03.011. PMID: 24746704

Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, Hu W, Beguelin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Huberman K, Bouvier N, Berger MF, Melnick AM, Rosen N, Tallman MS, Park CY, Abdel-Wahab O. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science Translational Medicine. 2014;6(238):238ra71. doi: 10.1126/scitranslmed.3008004. PMID: 24871132

Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nature Medicine. 2013;19(11):1401-9. doi: 10.1038/nm.3392. PMID: 24202393

Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012;22(5):668-82. doi: 10.1016/j.ccr.2012.10.009. PMID: 23153539

Lito P, Pantanowitz L, Marotti J, Aboulafia DM, Campbell V, Bower M, Dezube BJ. Gastroenteropancreatic neuroendocrine tumors in patients with HIV infection: a trans-Atlantic series. American Journal of Medical Sciences. 2009;337(1):1-4. doi: 10.1097/MAJ.0b013e31817d1cb7. PMID: 19155751

Lito P, Mets BD, Appledorn DM, Maher VM, McCormick JJ. Sprouty 2 regulates DNA damage-induced apoptosis in Ras-transformed human fibroblasts. The Journal of Biological Chemistry. 2009;284(2):848-54. doi: 10.1074/jbc.M808045200. PMID: 19008219

Lito P, Mets BD, Kleff S, O’Reilly S, Maher VM, McCormick JJ. Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts. The Journal of Biological Chemistry. 2008;283(4):2002-9. doi: 10.1074/jbc.M709046200. PMID: 18048363